Published in Nat Rev Drug Discov on December 23, 2016
The Effect of Arsenic Trioxide on Eliminating HIV-1 Reservoir Combined With cART | NCT03980665
How should the applications of genome editing be assessed and regulated? Elife (2017) 0.75
Opportunities and challenges in phenotypic drug discovery: an industry perspective. Nat Rev Drug Discov (2017) 0.75
Addressing Pressing Needs in the Development of Advanced Therapies. Front Bioeng Biotechnol (2017) 0.75
Personalized Therapy Against Preeclampsia by Replenishing Placental Protein 13 (PP13) Targeted to Patients With Impaired PP13 Molecule or Function. Comput Struct Biotechnol J (2017) 0.75
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
An integrated encyclopedia of DNA elements in the human genome. Nature (2012) 64.73
Multiplex genome engineering using CRISPR/Cas systems. Science (2013) 55.53
RNA-guided human genome engineering via Cas9. Science (2013) 48.29
A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science (2012) 48.17
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39
The ENCODE (ENCyclopedia Of DNA Elements) Project. Science (2004) 38.24
Comprehensive molecular characterization of human colon and rectal cancer. Nature (2012) 34.13
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
The double-strand-break repair model for recombination. Cell (1983) 31.21
Yeast transformation: a model system for the study of recombination. Proc Natl Acad Sci U S A (1981) 26.54
Cancer genome landscapes. Science (2013) 25.33
One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell (2013) 24.00
Derivation of completely cell culture-derived mice from early-passage embryonic stem cells. Proc Natl Acad Sci U S A (1993) 20.33
DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol (2013) 19.99
Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 18.90
Genome engineering using the CRISPR-Cas9 system. Nat Protoc (2013) 15.98
RNA-programmed genome editing in human cells. Elife (2013) 14.82
Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol (2008) 14.75
Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol (2013) 14.28
The druggable genome. Nat Rev Drug Discov (2002) 13.61
Development and applications of CRISPR-Cas9 for genome engineering. Cell (2014) 13.50
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell (2013) 13.37
Genome-scale CRISPR-Cas9 knockout screening in human cells. Science (2013) 12.36
Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med (2009) 11.68
CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol (2013) 11.35
Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science (2014) 10.43
CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell (2013) 9.55
One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. Cell (2013) 7.99
Model for homologous recombination during transfer of DNA into mouse L cells: role for DNA ends in the recombination process. Mol Cell Biol (1984) 7.99
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med (2014) 7.64
Cell cycle and genetic requirements of two pathways of nonhomologous end-joining repair of double-strand breaks in Saccharomyces cerevisiae. Mol Cell Biol (1996) 7.33
Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol (2014) 6.85
Efficient method to generate single-copy transgenic mice by site-specific integration in embryonic stem cells. Genesis (2006) 6.64
The repair of double-strand breaks in DNA; a model involving recombination. J Theor Biol (1976) 6.63
Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol (2010) 6.55
Embryonic stem cells alone are able to support fetal development in the mouse. Development (1990) 6.37
Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell (2014) 6.11
Central dogma of molecular biology. Nature (1970) 5.89
Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol (2014) 5.71
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol (2014) 5.69
Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature (2011) 5.68
Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. Cell (2014) 5.43
Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science (2009) 5.31
Nonhomologous recombination in mammalian cells: role for short sequence homologies in the joining reaction. Mol Cell Biol (1986) 5.25
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature (2014) 5.19
Haploid genetic screens in human cells identify host factors used by pathogens. Science (2009) 4.91
Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science (1993) 4.76
Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nat Biotechnol (2013) 4.72
Heritable gene targeting in the mouse and rat using a CRISPR-Cas system. Nat Biotechnol (2013) 4.58
Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nat Biotechnol (2014) 4.41
In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science (2015) 4.18
Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. Nat Biotechnol (2014) 4.16
Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A (2011) 4.15
Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature (2015) 3.77
Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds. Cell (2014) 3.76
Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. Nat Biotechnol (2014) 3.72
A rapid and scalable system for studying gene function in mice using conditional RNA interference. Cell (2011) 3.69
Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell (2015) 3.58
Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nat Biotechnol (2015) 3.56
High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature (2016) 3.54
Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system. Cell Res (2013) 3.50
Impact of the KU80 pathway on NHEJ-induced genome rearrangements in mammalian cells. Mol Cell (2004) 3.32
CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature (2014) 3.28
In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature (2014) 3.15
Identification and characterization of essential genes in the human genome. Science (2015) 3.14
Rationally engineered Cas9 nucleases with improved specificity. Science (2015) 3.14
Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science (2015) 2.97
In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science (2015) 2.85
Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood (2014) 2.84
Optimization of scarless human stem cell genome editing. Nucleic Acids Res (2013) 2.78
E-CRISP: fast CRISPR target site identification. Nat Methods (2014) 2.73
An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. Science (2013) 2.71
Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity (2013) 2.69
A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci U S A (2009) 2.61
Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nat Biotechnol (2001) 2.59
CRISPR/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences. Nucleic Acids Res (2014) 2.59
Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. Cell Stem Cell (2014) 2.55
Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics (2014) 2.54
Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat Med (2015) 2.43
Therapeutic genome editing: prospects and challenges. Nat Med (2015) 2.42
In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration. Nature (2016) 2.37
Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA. Nat Biotechnol (2016) 2.34
A protein-tagging system for signal amplification in gene expression and fluorescence imaging. Cell (2014) 2.27
Immune response to green fluorescent protein: implications for gene therapy. Gene Ther (1999) 2.27
Gene essentiality and synthetic lethality in haploid human cells. Science (2015) 2.26
Beta-thalassemia. Genet Med (2010) 2.24
Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature (2016) 2.15
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature (2015) 2.15
High frequency of homologous recombination in mammalian cells between endogenous and introduced SV40 genomes. Cell (1985) 2.14
Small molecule-triggered Cas9 protein with improved genome-editing specificity. Nat Chem Biol (2015) 2.13
Genome-wide inactivation of porcine endogenous retroviruses (PERVs). Science (2015) 2.07
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol (2016) 2.05
Biology and Applications of CRISPR Systems: Harnessing Nature's Toolbox for Genome Engineering. Cell (2016) 2.02
Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells. Blood (2015) 2.00
CCTop: An Intuitive, Flexible and Reliable CRISPR/Cas9 Target Prediction Tool. PLoS One (2015) 1.92
Nucleotide-resolution DNA double-strand break mapping by next-generation sequencing. Nat Methods (2013) 1.88
Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature (2014) 1.86
Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. Nat Biotechnol (2015) 1.83